featured
Effects of the SGLT2 Inhibitor Dapagliflozin on Glomerular and Tubular Injury Markers
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effects of the SGLT-2 Inhibitor Dapagliflozin on Glomerular and Tubular Injury Markers
Diabetes Obes Metab 2018 Mar 24;[EPub Ahead of Print], CCJ Dekkers, S Petrykiv, GD Laverman, DZ Cherney, RT Gansevoort, HJL HeerspinkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.